© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Liver Meeting 2015
Click Here for More Conferences
Click Here for AASLD.org
An Introduction to Hepatitis

Conferences

Oriol R. Gutierrez

Pretty Woman

Getting access to the new hep C drugs remains an ongoing barrier for too many people, but the drugs keep getting better.

High Marks for Merck’s Hep C Treatment in Those With HIV

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Success in Adding Sovaldi to Hep C Re-treatment Regimens

Individuals who have failed hepatitis C treatment may ultimately achieve a cure if they add Sovaldi (sofosbuvir) to a subsequent treatment reg...

Less Liver Fibrosis for Coffee Drinkers With Hep B or C

Drinking coffee is linked with reduced liver fibrosis among people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease.

Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4

Twelve or 16 weeks of Sovaldi (sofosbuvir) and ravidasvir cured high rates of people with genotype 4 of hepatitis C virus in a recent large tr...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

More Good Hep C Cure Rates for Sovaldi/Velpatasvir

Sovaldi and velpatasvir, with/without ribavirin, yielded good results among people with various genotypes of HCV and decompensated cirrhosis

Gilead’s Sovaldi/Velpatasvir Cures High Rates of All Hep C Genotypes

Gilead Sciences Sovaldi (sofosbuvir) and velpatasvir posted near-perfect results in curing an array of genotypes of hepatitis C.

8 Weeks of Harvoni + Vedroprevir Cures 96% of Hard-to-Treat Hep C

8 weeks of Harvoni (ledipasvir/sofosbuvir) and vedroprevir boasted a near-perfect cure rate among those with genotype 1 and advanced liver dis...

Daklinza & Sovaldi Better Treats Those With HIV & HCV

Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...

Hepatitis C Cure Often Leads to Improvement in Liver Health

Those with advanced fibrosis or cirrhosis who are cured of hepatitis C often experience regression of liver damage, improving by at least one...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Reflections of a Hepatitis C Advocate

Long time health advocate Bill Remak’s reflections on the 2015 AASLD Liver Meeting and hepatitis C advocacy

High Genotype 2 and 3 Hep C Cure Rates for New AbbVie Combo

AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3.

Near-Perfect Results for New AbbVie Hep C Combo in Genotype 1s

Eight or 12 weeks of AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 cured 97 to 100 percent of people with genotype 1.

Promising Results for REP 2139 Treating Hep B and D Coinfection

A nucleic acid-based polymer called REP 2139, given alone and with interferon, has shown promise treating coinfection with hep B and hep D.

Today’s Hep C Drugs May Avert Many Liver Transplants

The high success rate of today’s hepatitis C treatments may keep many people from needing a liver transplant.
Advertisement
Science News
Newsfeed
Features
Ask Hep

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.